Pharmaceutical advertising is the second leading source of health information for patients. AI can “de-criminalize” it by moving from untrackable broadcast ads to programmatic, personalized, and compliant digital content, turning it into a valuable and trusted patient resource monitored by the government.
The core issue preventing a patient-centric system is not a lack of technological capability but a fundamental misalignment of incentives and a deep-seated lack of trust between payers and providers. Until the data exists to change incentives, technological solutions will have limited impact.
The immense regulatory complexity in U.S. healthcare creates an estimated $500 billion "tax" of administrative bloat. The non-obvious opportunity is that by using AI to eliminate this waste, the savings could be redirected to fund expanded patient care, rather than just being captured as profit.
Contrary to advisors who predicted EHRs would quickly fix healthcare data, Matt Holt invested in HealthPort, believing the system's deep brokenness provided a 15-20 year runway. The insight is that intractable, systemic fragmentation creates durable opportunities for foundational infrastructure players.
An "AI arms race" is underway where stakeholders apply AI to broken, adversarial processes. The true transformation comes from reinventing these workflows entirely, such as moving to real-time payment adjudication where trust is pre-established, thus eliminating the core conflict that AI is currently used to fight over.
An early, painful experience as acting CFO for a surgery center that struggled to get paid—a deal nicknamed "Death by a Thousand Cuts"—directly shaped the firm's successful healthcare strategy. This scar tissue led to a vow to avoid direct care provision and focus exclusively on less glamorous but more defensible IT and data infrastructure.